# A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

> **NCT05569759** · PHASE2 · COMPLETED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Autoimmune Hepatitis

## Interventions

- **DRUG:** zetomipzomib
- **DRUG:** placebo
- **DRUG:** zetomipzomib in open-label extension

## Key facts

- **NCT ID:** NCT05569759
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-23
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569759, "A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05569759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*